"Rescue" regimens after Helicobacter pylori treatment failure
- PMID: 18803350
- PMCID: PMC2744171
- DOI: 10.3748/wjg.14.5385
"Rescue" regimens after Helicobacter pylori treatment failure
Abstract
Helicobacter pylori (H pylori) infection is the main cause of gastritis, gastroduodenal ulcer disease, and gastric cancer. After more than 20 years of experience in H pylori treatment, in my opinion, the ideal regimen to treat this infection is still to be found. Currently, apart from having to know first-line eradication regimens well, we must also be prepared to face treatment failures. Therefore, in designing a treatment strategy we should not focus on the results of primary therapy alone, but also on the final (overall) eradication rate. The choice of a "rescue" treatment depends on which treatment is used initially. If a clarithromycin-based regimen was used initially, a subsequent metronidazole-based treatment (quadruple therapy) may be used afterwards, and then a levofloxacin-based combination would be a third "rescue" option. Alternatively, it has recently been suggested that levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous PPI-clarithromycin-amoxicillin failure, with the advantage of efficacy, simplicity and safety. In this case, a quadruple regimen may be reserved as a third-line rescue option. Finally, rifabutin-based rescue therapy constitutes an encouraging empirical fourth-line strategy after multiple previous eradication failures with key antibiotics such as amoxicillin, clarithromycin, metronidazole, tetracycline, and levofloxacin. Even after two consecutive failures, several studies have demonstrated that H pylori eradication can finally be achieved in almost all patients if several rescue therapies are consecutively given. Therefore, the attitude in H pylori eradication therapy failure, even after two or more unsuccessful attempts, should be to fight and not to surrender.
Figures



Similar articles
-
Second-line rescue therapy of helicobacter pylori infection.Therap Adv Gastroenterol. 2009 Nov;2(6):331-56. doi: 10.1177/1756283X09347109. Therap Adv Gastroenterol. 2009. PMID: 21180581 Free PMC article.
-
Rescue Therapy for Helicobacter pylori Infection 2012.Gastroenterol Res Pract. 2012;2012:974594. doi: 10.1155/2012/974594. Epub 2012 Feb 28. Gastroenterol Res Pract. 2012. PMID: 22536225 Free PMC article.
-
'Rescue' therapies for the management of Helicobacter pylori infection.Dig Dis. 2006;24(1-2):113-30. doi: 10.1159/000090315. Dig Dis. 2006. PMID: 16699270 Review.
-
Helicobacter pylori "rescue" therapy after failure of two eradication treatments.Helicobacter. 2005 Oct;10(5):363-72. doi: 10.1111/j.1523-5378.2005.00324.x. Helicobacter. 2005. PMID: 16181345 Review.
-
Helicobacter pylori eradication therapy.Future Microbiol. 2010 Apr;5(4):639-48. doi: 10.2217/fmb.10.25. Future Microbiol. 2010. PMID: 20353303 Review.
Cited by
-
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.PLoS One. 2013 Jul 25;8(7):e68917. doi: 10.1371/journal.pone.0068917. Print 2013. PLoS One. 2013. PMID: 23935905 Free PMC article.
-
[Modern Helicobacter pylori therapies in times of increasing anti biotic resistance].Med Klin (Munich). 2010 Nov;105(11):787-91. doi: 10.1007/s00063-010-1135-2. Epub 2010 Dec 7. Med Klin (Munich). 2010. PMID: 21136236 Review. German.
-
Research on antibiotic resistance in Helicobacter pylori: a bibliometric analysis of the past decade.Front Microbiol. 2023 Jun 14;14:1208157. doi: 10.3389/fmicb.2023.1208157. eCollection 2023. Front Microbiol. 2023. PMID: 37389333 Free PMC article.
-
Dual therapy for third-line Helicobacter pylori eradication and urea breath test prediction.World J Gastroenterol. 2012 Jun 7;18(21):2735-8. doi: 10.3748/wjg.v18.i21.2735. World J Gastroenterol. 2012. PMID: 22690086 Free PMC article.
-
Comparison of Levofloxacin-Based, 10-day Sequential Therapy with 14-day Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial.Middle East J Dig Dis. 2018 Oct;10(4):242-248. doi: 10.15171/mejdd.2018.117. Epub 2018 Sep 6. Middle East J Dig Dis. 2018. PMID: 31049172 Free PMC article.
References
-
- Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2330–2338. - PubMed
-
- Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G. Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167–180. - PubMed
-
- Gisbert JP, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, Gabriel R, Pajares JM. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther. 2000;14:1319–1328. - PubMed
-
- Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter. 2007;12 Suppl 2:50–58. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical